Photo courtesy of Yonhap News

 

[Alpha Biz= Paul Lee] Yuhan Corporation has signed a new active pharmaceutical ingredient (API) supply agreement with Gilead Sciences, reinforcing its position in the global pharma supply chain.

The company disclosed on May 20 that it entered into a contract worth $139.81 million (approximately KRW 210 billion) on May 19. The deal represents about 9.6% of Yuhan’s annual revenue.

The contract does not include upfront payments or advance fees and will run through December 31, 2027.

Under Yuhan’s business structure, production of the APIs will be handled by its subsidiary Yuhan Chemical.

This marks a continuation of the partnership between the two companies. In 2024, Yuhan signed separate API supply agreements with Gilead for HIV and hepatitis C treatments, valued at KRW 88.8 billion and KRW 85.0 billion, respectively.

The latest deal underscores Yuhan’s expanding role as a key manufacturing partner for global pharmaceutical firms, particularly in the supply of essential drug ingredients.

 

 

 

[ⓒ 메디컬투데이. 무단전재-재배포 금지]